SYNERGY™

Everolimus-Eluting Platinum Chromium Coronary Stent System

SYNTAX II: CABG-LIKE OUTCOMES WITH SYNERGY™ BP STENT AND STATE-OF-THE-ART PCI STRATEGY

The SYNTAX II Trial evaluated the SYNERGY™ BP-EES Stent in a procedure-related trial involving a multitude of variables when treating patients with three-vessel disease including:
The SYNTAX II Trial evaluated the SYNERGYTM BP-EES Stent

The 12 month results were then compared to the PCI and CABG arms of the original SYNTAX I Trial as historical comparators. So what did we learn?

PHYSIOLOGY

We learned that the right patients were treated for the right reasons when physiology (FFR/iFR) is utilized.
Physiology trial results in deferring of intervention

CROSSING

We learned that contemporary CTO PCI in SYNTAX II Trial demonstrated a significantly higher procedural success rate compared to those in SYNTAX I.

PCI with CTO procedural success rates jumped from 53% in SYNTAX I to 87% in SYNTAX II. That represents a 64% increase in successful CTO treatment.

TREATMENT

We learned that SYNERGY™ BP-EES together with other contemporary technologies and techniques proved PCI could be an option for patients with complex three-vessel disease.

Low rates of revascularization, peri-procedural MI and acute ST suggest that SYNERGY BP-EES might help in reducing procedural related complications.

STENT OPTIMIZATION

We learned that IVUS helps to optimize stent placement and achieve better outcomes when used as a part of contemporary PCI.

Post-Implantation IVUS was performed in 84% of patients leading to further stent optimization in 30% of lesions.

SYNTAX II shows that physiological assessment, contemporary CTO techniques, use of the SYNERGY BP-EES Stent, and IVUS guidance demonstrate CABG-like outcomes in patients with three-vessel disease. Boston Scientific has a minimally-invasive complete revascularization portfolio to address these needs for patients. Contact a rep today for more information.
Top